SI-BONE, Inc. , a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally.
Si Bone stock last closed at $24.27, down 1.1% from the previous day, and has increased 71.16% in one year. It has overperformed other stocks in the Medical Devices industry by 0.73 percentage points. Si Bone stock is currently +117.86% from its 52-week low of $11.14, and -10.9% from its 52-week high of $27.24.
As of May 26, 2023, there are 35.18M SIBN shares outstanding. The market cap of SIBN is $853.92M. In the past 24 hours, 202,194 SIBN shares were traded.
You need a brokerage account in order to access the NASDAQ market and buy SIBN stock.
Based on our analysis, eToro is the best stock brokerage. eToro gives you:
Get $10 towards your purchase of shares by signing up for an account with eToro now.Open eToro Account
Now that you've picked your brokerage, the next step is to fill out some personal information so you can buy SIBN today.
Now that you have opened your account on app for investing, you can securely and quickly fund your account:
Check out this video walkthrough to see the process of transferring funds into your investment account.
After you have decided on the best place to buy Si Bone stock, it's crucial to evaluate their stock prior to investing, so you truly wrap your head around the risk as well as the upside.
WallStreetZen was built to help everyday investors perform more accurate fundamental analysis in less time.
You can view all of the due diligence checks on SIBN's stock page.
You can use a variety of different financial metrics, analyses, models, and charts to gauge SIBN's fair value.
Using relative valuations ratios:
You can do additional valuation research on SIBN's stock here.
Out of 7 Wall Street analysts who give recommendations on SIBN, the consensus analyst rating on SIBN is a Strong Buy
It's important to keep in mind that analyst ratings are not stock recommendations, nor are they financial advice.
Ross Osborn, a bottom 20% analyst from Cantor Fitzgerald maintains SIBN with a strong buy rating and raises their SIBN price target from $24.00 to $30.00, on May 2, 2023.
Drew Ranieri, a top 23% analyst from Morgan Stanley maintains SIBN with a strong buy rating and raises their SIBN price target from $22.00 to $27.00, on May 2, 2023.
David Turkaly, a bottom 8% analyst from JMP Securities reiterates SIBN with a buy rating and maintains their SIBN price target from $32.00 to $32.00, on May 2, 2023.
Kyle Rose, a top 4% analyst from Canaccord Genuity maintains SIBN with a strong buy rating and raises their SIBN price target from $24.00 to $27.00, on May 2, 2023.
Maintaining his Strong Buy rating, Rose raised his price target on SI-Bone Inc. by 12.5% following the release of the company's Q1 2023 earnings report on 2023/05/01.
Investors should "take a hard look" at SI-Bone ahead of "a potentially prolonged period of execution in 2023," the analyst recommended, arguing that investments in commercial infrastructure and reimbursement tailwinds "will translate to productivity gains and upside to estimates for SI-Bone through 2023 and beyond."
For Q1 2023, SI-Bone reported:
Management updated its FY 2023 guide:
CEO Laura Francis commented, “I am thrilled with our stellar start to 2023, as record procedure demand in the quarter allowed us to deliver approximately 50% U.S. revenue growth and achieve significant operating leverage.
“The continued trend of accelerating revenue growth over the last several quarters is a testament to the strong reception for our expanded portfolio of solutions.
"With yet another quarter of record increase in our active surgeon base combined with the favorable reimbursement framework, we are at an inflection in the business.
"These trends solidify my conviction in our ability to deliver strong and sustainable growth and drive operating leverage as we progress through the year."
David Saxon, a bottom 23% analyst from Needham maintains SIBN with a buy rating and raises their SIBN price target from $24.00 to $27.00, on May 2, 2023.
You can dig deeper into what analysts are projecting on the Si Bone stock forecast page.
Last year, SIBN revenue was $116.68M. In the past four year, SIBN's revenue has grown by 19.27% per year. This was faster than the Medical Devices industry average of 12.46%.
Dive into SIBN's earnings and revenue performance here.
Over the last year, executives and large shareholders at SIBN have sold more shares than they have bought.
Anthony J. Recupero, President Commercial Ops of SIBN, was the latest SIBN insider to sell. They sold $74,643.28 worth of SIBN shares on May 17, 2023.
Get more info about who owns SIBN shares here.
No, Si Bone doesn't provide an income stream by paying out dividends.
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other traders have to say.
There are two main order types:
Press the Open button and eToro will execute the order.
If you require more help with investing in stocks on eToro, click the helpful video below:
Now that you own some SIBN shares, you'll want to keep up with your new shares.
Create a watchlist to get notified of important updates regarding your SIBN stock.
To summarize, here are the 6 steps to buy stock in Si Bone:
If you need a brokerage, eToro is our favorite venue.Get Started with eToro Today
If you want to get the latest scoop on your new investment in Si Bone, add SIBN to your watchlist below.
How much does it cost to buy one Si Bone share?
Is now a good time to buy Si Bone stock?
What is the best way to buy Si Bone stock?